Four species of the genus Ebolavirus cause severe and often lethal disease in humans: Sudan ebolavirus (SUDV), Bundibugyo ebolavirus (BDBV), Taï Forest ebolavirus (TAFV), and Zaire ebolavirus (EBOV)[1]. Historically, EBOV has caused most Ebolavirus outbreaks and cases. The devastating 2013 to 2016 EBOV epidemic in West Africa, resulting in approximately 29,000 cases, prompted the global community to rapidly advance vaccine candidates that were previously in nascent stages of development [2]. The recent reemergence of EBOV in Guinea, Uganda, and the Democratic Republic of Congo (DRC) emphasizes the continued need for safe and effective vaccines against this deadly pathogen along with optimal deployment strategies. Heroic efforts by countless volunteers and organizations to vaccinate contacts of confirmed patients, healthcare staff, and frontline workers helped curb the West Africa epidemic and these more recent flare-ups [3, 4]. As the global community was better prepared for the latter, a quick vaccination response was implemented that significantly abated transmission [4]. While EBOV outbreaks have historically impacted relatively small numbers of people on a global scale, they have caused great suffering and have inflicted an enormous economic toll in endemic countries. Demonstrated exportation of the virus to nonendemic regions [2, 5] along with the bioweapon potential of ebolaviruses further warrant the development of EBOV vaccines worldwide.